Skip to main content
. 2017 Apr 8;14(5):425–433. doi: 10.7150/ijms.18037

Figure 4.

Figure 4

Isoflurane, RAP, or MG-132 treatment inhibited LRP/NF-κB/Cox-2 pathway and MMP-2 and MMP-9 activities. (A and B) Isoflurane pretreatment significantly reduced NF-κB expression in the tPA and OGD/R condition; RAP and isoflurane + RAP treatment also reduced NF-κB p65 in the tPA and OGD/R condition. (C, D, and E) Isoflurane pretreatment significantly reduced NF-κB and Cox-2 expression in the tPA and OGD/R condition; MG-132 and isoflurane + MG-132 treatment reduced NF-κB p65 and Cox-2 in the tPA and OGD/R condition. To measure the activity of MMP-2 and MMP-9 after treatment with RAP or MG-132, we performed an activity assay. (F and G) Isoflurane pretreatment significantly reduced the activities of MMP-2 and MMP-9 under tPA and OGD/R condition. RAP and isoflurane + RAP treatment reduced the activities of MMP-2 and MMP-9 in the tPA and OGD/R condition. (H and I) MG-132and isoflurane + MG-132 treatment reduced the activities of MMP-2 and MMP-9 in the tPA and OGD/R condition. *p< 0.05, **p< 0.01, ***p< 0.001, the one-way ANOVA (means ± SEM, OD of NF-κB, and Cox-2 (n=3), Active MMP-2 (ng/mL) (n=3), Active MMP-9 (ng/mL) (n=3-4))